Thermo Fisher Scientific Inc. $TMO Shares Sold by Central Bank & Trust Co.

Central Bank & Trust Co. lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 70.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 539 shares of the medical research company’s stock after selling 1,274 shares during the period. Central Bank & Trust Co.’s holdings in Thermo Fisher Scientific were worth $364,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Dakota Community Bank & Trust NA boosted its holdings in shares of Thermo Fisher Scientific by 53.8% in the 3rd quarter. Dakota Community Bank & Trust NA now owns 203 shares of the medical research company’s stock worth $137,000 after acquiring an additional 71 shares in the last quarter. Graves Light Lenhart Wealth Inc. bought a new position in Thermo Fisher Scientific in the 3rd quarter valued at $208,000. Chapin Davis Inc. acquired a new position in Thermo Fisher Scientific in the third quarter worth $209,000. Inspirion Wealth Advisors LLC bought a new stake in shares of Thermo Fisher Scientific during the third quarter worth $236,000. Finally, Monument Capital Management increased its stake in shares of Thermo Fisher Scientific by 20.8% in the third quarter. Monument Capital Management now owns 1,016 shares of the medical research company’s stock valued at $686,000 after buying an additional 175 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Wells Fargo & Company downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research report on Wednesday, September 9th. UBS Group upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and raised their price objective for the company from $540.00 to $730.00 in a research report on Tuesday, September 8th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 28th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 3rd. Finally, Citigroup cut shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research report on Wednesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $634.86.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Michael Shafer sold 25,500 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares in the company, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 73,768 shares of company stock worth $44,122,820. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.3%

Shares of NYSE:TMO traded up $8.17 during trading on Friday, hitting $660.15. 493,268 shares of the company’s stock were exchanged, compared to its average volume of 2,244,326. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The firm has a market cap of $244.09 billion, a P/E ratio of 35.49, a PEG ratio of 2.77 and a beta of 0.87. The firm has a 50-day moving average price of $625.73 and a two-hundred day moving average price of $540.54. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $694.33.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.